Kidney Cancer in Black Adults: Higher Risk, Worse Survival

Renal cell carcinoma (RCC) is the most common form of kidney cancer, accounting for roughly 9 in 10 cases. It starts in the tiny tubes that filter your blood. Black Americans develop it more often than white Americans and survive it less often, a gap that holds even though Black patients are usually diagnosed with smaller, lower-stage tumors. The reasons are not mysterious: a heavier burden of high blood pressure and chronic kidney disease drives the higher risk, and lower rates of curative surgery widen the survival gap. Both ends of that problem have known fixes.

Kidney cancer is not one disease. RCC has several subtypes, and they behave differently. Clear cell RCC is the most common type in everyone. Papillary RCC is the second most common, and this is where Black patients differ: papillary RCC shows up far more often in Black patients. In one national SEER analysis, papillary RCC made up 12.5% of cases in Black patients versus 4.5% in white patients, while clear cell made up 77.9% versus 88.6%. Subtype matters because it shapes how a tumor is likely to grow and which drugs work against it if the cancer spreads.

Black Americans carry a higher incidence of kidney cancer, and the rise in cases over recent decades has been steeper in Black Americans than white Americans. The American Cancer Society lists kidney cancer as more common in African American, American Indian, and Alaska Native people.

The harder part of the story is survival. Black patients tend to be diagnosed earlier, with smaller tumors, which should predict better outcomes. The opposite happens. In a SEER analysis of 70,059 RCC patients, 81.8% of Black patients had small T1 tumors versus 73.5% of white patients, yet Black patients had 27% greater odds of dying from any cause. A separate national SEER study found Black patients had a five-year survival of 68.0% versus 72.6% for white patients, and that lower rates of surgery explained much of the gap.

Why does an earlier diagnosis not translate into better survival? Two threads run through the research. First, treatment gaps. In the same SEER study, Black patients had 18% lower odds of getting a nephrectomy, the surgery that removes the tumor and is the main path to a cure for localized disease. Second, comorbidity. Black patients more often carry high blood pressure, obesity, diabetes, and chronic kidney disease at diagnosis, conditions that complicate surgery, limit treatment options, and shorten survival on their own.

The strongest established risk factors for RCC are smoking, obesity, and high blood pressure. Smoking roughly doubles the risk and is tied to as many as a third of cases. For Black patients, hypertension is the lever that matters most. A study estimating population attributable risk across two US populations found high blood pressure accounted for a far larger share of RCC cases in Black Americans, on the order of 44% to 50% in Black men and women, compared with roughly 27% to 29% in white Americans. The authors concluded that preventing hypertension and chronic kidney disease in Black Americans could, in theory, erase the racial gap in kidney cancer incidence.

Chronic kidney disease (CKD) is its own independent risk factor, and the link is stronger in Black patients. A Kaiser Permanente case-control study of 3,136 RCC cases reported that CKD raised RCC risk and that hypertension and CKD together likely drove much of the excess kidney cancer seen in Black patients versus white patients. People on long-term dialysis face added risk from acquired cystic kidney disease. This is the through-line for Black readers: the same conditions that already hit Black communities hardest, high blood pressure and kidney disease, are the conditions that feed kidney cancer risk. Getting blood pressure controlled and kidney function checked is cancer prevention, not just heart and kidney care.

If you have high blood pressure or early kidney disease, those numbers are a reason to act, not to worry in place. Our guide to high blood pressure in Black men covers what tight control actually takes, and our explainer on kidney disease and the APOL1 gene explains why Black Americans face higher rates of CKD in the first place.

Most early kidney cancer causes no symptoms at all. More than half of RCC cases are found incidentally, picked up on a CT scan or ultrasound ordered for an unrelated problem. The classic triad of blood in the urine, flank pain, and a mass you can feel is now uncommon and usually signals advanced disease. When symptoms do appear, they can include:

• Blood in the urine (pink, red, or cola-colored), which may come and go
• Pain or a dull ache in the side or lower back that does not go away
• A lump or mass in the side or belly
• Unexplained weight loss
• Persistent fatigue
• A fever that is not from an infection
• Anemia, low blood counts found on routine bloodwork

Because the early disease is silent, the most reliable way many people learn they have it is through imaging done for another reason. That makes it worth getting blood in the urine checked promptly rather than waiting to see if it clears.

When a kidney mass turns up, the workup centers on imaging. A contrast-enhanced CT scan is the preferred test and detects about 90% of renal masses, showing whether a growth looks benign or cancerous and whether it has spread. MRI is used when CT is not an option, such as in pregnancy or contrast allergy. A needle biopsy is sometimes done, though many kidney tumors go straight to surgery based on imaging.

Treatment depends on stage. For localized tumors, surgery is the main path to a cure. A partial nephrectomy removes only the tumor and spares the rest of the kidney, which protects long-term kidney function and is preferred when feasible. A radical nephrectomy removes the whole kidney and is used for larger or more complex tumors. For small tumors, thermal ablation (cryoablation or radiofrequency ablation) can destroy the growth without major surgery, and active surveillance is reasonable for very small masses in selected patients. For cancer that has spread, treatment uses immunotherapy (checkpoint inhibitors) and targeted therapy (drugs that block tumor blood supply, such as VEGF and tyrosine kinase inhibitors), often in combination.

The treatment gap is where Black patients lose ground. When fewer Black patients with curable, localized tumors get to surgery, survival drops even though the cancer was caught early. That is a fixable, system-level problem, and it is a reason to be an active participant in your own care: ask whether surgery is on the table, and whether a kidney-sparing partial nephrectomy is an option for you.

Start with the conditions you can control today. Get your blood pressure to goal, ask for a kidney function check (a blood eGFR and a urine test), and stop smoking if you smoke. Those steps lower your kidney cancer risk and protect your kidneys and heart at the same time. If a kidney mass is found, ask directly whether surgery is recommended and whether a partial nephrectomy can spare your kidney. A clinician who listens and follows through matters, especially given the documented treatment gaps. You can find a Black or Black-serving clinician in our directory to lead that conversation.